DK0402300T3 - Fremstilling i bakterier af gær og hæmoglobin og analoger dertil - Google Patents

Fremstilling i bakterier af gær og hæmoglobin og analoger dertil

Info

Publication number
DK0402300T3
DK0402300T3 DK90610036.7T DK90610036T DK0402300T3 DK 0402300 T3 DK0402300 T3 DK 0402300T3 DK 90610036 T DK90610036 T DK 90610036T DK 0402300 T3 DK0402300 T3 DK 0402300T3
Authority
DK
Denmark
Prior art keywords
hemoglobin
polypeptide
alpha
yeast
analogues
Prior art date
Application number
DK90610036.7T
Other languages
Danish (da)
English (en)
Inventor
Stephen J Hoffman
Douglas L Looker
Mary S Rosendal
Gary L Stetler
Michael Wagenbach
Kiyoshi Nagai
Original Assignee
Medical Res Council
Somatogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Somatogen Inc filed Critical Medical Res Council
Application granted granted Critical
Publication of DK0402300T3 publication Critical patent/DK0402300T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445Haemoglobin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
DK90610036.7T 1989-05-10 1990-05-10 Fremstilling i bakterier af gær og hæmoglobin og analoger dertil DK0402300T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34962389A 1989-05-10 1989-05-10
US37416189A 1989-06-30 1989-06-30
US37911689A 1989-07-13 1989-07-13

Publications (1)

Publication Number Publication Date
DK0402300T3 true DK0402300T3 (da) 1996-09-30

Family

ID=27407902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90610036.7T DK0402300T3 (da) 1989-05-10 1990-05-10 Fremstilling i bakterier af gær og hæmoglobin og analoger dertil

Country Status (18)

Country Link
EP (3) EP0700997B1 (fr)
JP (1) JP3013902B2 (fr)
KR (1) KR920701434A (fr)
AT (2) ATE142692T1 (fr)
AU (1) AU635744B2 (fr)
CA (1) CA2050601C (fr)
DE (2) DE69028448T2 (fr)
DK (1) DK0402300T3 (fr)
ES (2) ES2093640T3 (fr)
FI (2) FI105104B (fr)
GR (1) GR3021106T3 (fr)
HU (1) HUT61591A (fr)
IE (1) IE970086A1 (fr)
IL (1) IL94361A (fr)
NO (2) NO304027B1 (fr)
NZ (1) NZ233642A (fr)
SG (1) SG47987A1 (fr)
WO (1) WO1990013645A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US6204009B1 (en) 1988-05-16 2001-03-20 BAXTER BIOTECH TECHNOLOGY SàRL Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
US6150506A (en) * 1989-05-10 2000-11-21 Baxter Biotech Technology Sarl Modified hemoglobin-like compounds and methods of purifying same
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5844090A (en) * 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
WO1991013158A1 (fr) * 1990-02-28 1991-09-05 Delta Biotechnology Limited Production de proteines dans la levure
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
ATE222600T1 (de) * 1990-04-16 2002-09-15 Apex Bioscience Inc Expression von rekombinantem hämoglobin in hefe
WO1992011283A1 (fr) * 1990-12-20 1992-07-09 The University Of Alabama Research Foundation Hemoglobine transgenique reticulee
US5610137A (en) * 1990-12-20 1997-03-11 The Uab Research Foundation Transgenic, cross-linked hemoglobin
GB9028062D0 (en) * 1990-12-24 1991-02-13 Agricultural & Food Res Production of transgenic animals
US5714345A (en) * 1990-12-24 1998-02-03 Pharmaceutical Proteins Limited Increased expression of a gene by a second transferred mammary gland specific sequence transgenic
WO1993008831A1 (fr) * 1991-10-30 1993-05-13 Strohtech, Inc. Expression d'hemoglobine recombinee et de variants d'hemoglobine recombines dans des levures
CA2122717C (fr) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobines utilisees comme agents d'administration de medicaments
FR2688784B1 (fr) * 1992-03-18 1995-06-30 Pasteur Merieux Serums Vacc Transporteur d'oxygene.
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
EP0691988B1 (fr) 1993-03-31 2002-10-02 Pro-Neuron, Inc. Inhibiteur de la proliferation de cellules souche et ses utilisations
US6610654B2 (en) 1993-03-31 2003-08-26 Wellstat Therapeutics Corporation Inhibitor of stem cell proliferation and uses thereof
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US6140071A (en) * 1994-01-27 2000-10-31 Somatogen, Inc. Proteins with mutations to decrease N-terminal methylation
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU6489996A (en) * 1995-07-14 1997-02-18 Somatogen, Inc. Methods for increasing protein expression
US5824511A (en) * 1995-08-01 1998-10-20 University Technology Corporation Method for enhancing the production of hemoproteins
WO1997015591A1 (fr) * 1995-10-23 1997-05-01 Rice University Mutants d'hemoglobine reduisant la perte d'hemes
US6812207B1 (en) 1995-10-23 2004-11-02 William Marsh Rice University Hemoglobin mutants that reduce heme loss
EP0863918A1 (fr) * 1995-11-30 1998-09-16 Somatogen Inc. Methode de regulation de fonctionnalite au cours de la reticulation des hemoglobines
CA2239303A1 (fr) 1995-12-22 1997-07-03 Somatogen, Inc. Globines incluant des domaines de liaison
WO1997023631A2 (fr) * 1995-12-22 1997-07-03 Somatogen, Inc. Globines incluant des domaines de liaison
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
AU4990697A (en) * 1996-10-18 1998-05-15 Eli Lilly And Company Methods of reducing the levels of protoporphyrin ix in recombinant hemoglobin preparations
EP1950298A3 (fr) 1997-05-02 2008-12-24 Baxter Biotech Technology S.A.R.L. Mutants d'hémoglobine dotés d'une expression soluble accrue et/ou d'une évacuation réduite de l'oxyde nitrique
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
CA2438074C (fr) 2001-03-09 2013-09-17 Genentech, Inc. Procede de production de polypeptides
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US20100204128A1 (en) * 2007-07-24 2010-08-12 Sanare Investment As Novel peptides
EP2058398A1 (fr) * 2007-11-09 2009-05-13 Nipro Corporation Production d'hémoglobine humaine recombinante à l'aide de levure Pichia
KR101584540B1 (ko) * 2014-04-16 2016-01-14 박병용 대형 식품용기 자동 세척장치
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
WO2021140488A1 (fr) * 2020-01-10 2021-07-15 Intron Biotechnology, Inc. Procédé de préparation de myoglobine bovine à l'aide d'escherichia coli
CN114929736A (zh) * 2020-01-10 2022-08-19 尹特荣生物科技株式会社 一种利用大肠杆菌制备猪肌红蛋白的方法
CN116203144B (zh) * 2022-05-11 2023-10-27 重庆医科大学附属儿童医院 测定血红蛋白中各型珠蛋白链比率的方法及其应用
CN118108834A (zh) * 2022-11-30 2024-05-31 康码(上海)生物科技有限公司 重组血红蛋白

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3924943A (en) 1974-06-11 1975-12-09 Xerox Corp Segmented biased transfer member
US4769326A (en) 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8412517D0 (en) 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4774180A (en) 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
GB8701001D0 (en) 1987-01-19 1987-02-18 Gordon D G Ceiling tiles
WO1988006601A1 (fr) 1987-03-02 1988-09-07 Genex Corporation Represseurs de genes
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0561245A1 (fr) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Produits de remplacement du sang comprenant d'hémoglobine recombinante

Also Published As

Publication number Publication date
NO315568B1 (no) 2003-09-22
ES2093640T3 (es) 1997-01-01
EP0402300B1 (fr) 1996-09-11
DE69034091T2 (de) 2004-04-22
ATE246246T1 (de) 2003-08-15
GR3021106T3 (en) 1996-12-31
CA2050601A1 (fr) 1990-11-11
JP3013902B2 (ja) 2000-02-28
DE69028448D1 (de) 1996-10-17
IE970086A1 (en) 2000-02-23
KR920701434A (ko) 1992-08-11
NO304027B1 (no) 1998-10-12
NO914387L (no) 1991-11-08
ES2204926T3 (es) 2004-05-01
WO1990013645A1 (fr) 1990-11-15
FI105104B (fi) 2000-06-15
SG47987A1 (en) 1998-04-17
EP0402300A3 (fr) 1991-01-30
NO973848D0 (no) 1997-08-21
AU635744B2 (en) 1993-04-01
HU905111D0 (en) 1992-02-28
EP0402300A2 (fr) 1990-12-12
ATE142692T1 (de) 1996-09-15
CA2050601C (fr) 2000-09-19
NO914387D0 (no) 1991-11-08
JPH05503627A (ja) 1993-06-17
FI915279A0 (fi) 1991-11-08
EP0700997A1 (fr) 1996-03-13
EP1380645A2 (fr) 2004-01-14
HUT61591A (en) 1993-01-28
EP0700997B1 (fr) 2003-07-30
IL94361A0 (en) 1991-03-10
NZ233642A (en) 1992-12-23
FI107938B (fi) 2001-10-31
NO973848L (no) 1997-08-21
FI20000025A (fi) 2000-01-05
AU5675690A (en) 1990-11-29
IL94361A (en) 1995-07-31
DE69034091D1 (de) 2003-09-04
DE69028448T2 (de) 1997-02-06

Similar Documents

Publication Publication Date Title
DK0402300T3 (da) Fremstilling i bakterier af gær og hæmoglobin og analoger dertil
DE3650538D1 (de) Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
ATE61407T1 (de) Muteine biologisch aktiver proteine mit verringertem cysteingehalt, ihre herstellung, formulierungen, die solche muteine enthalten sowie strukturgene, vektoren und organismen, die zur herstellung der genannten muteine geeignet sind und deren herstellung.
DE3851153D1 (de) Genetische modifizierung von endothelialen zellen.
DE3851225D1 (de) Blutersatz.
ATE142264T1 (de) Rekombinante herstellung von a-ketten- polypeptiden von pdgf
ATE109206T1 (de) O-glycosylierter igf-1.